Gotham Asset Management LLC Has $23.30 Million Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Gotham Asset Management LLC increased its holdings in Charles River Laboratories International, acquiring an additional 31,087 shares, bringing its total ownership to 154,777 shares, valued at approximately $23.3 million.
• The company's recent earnings report showed an EPS of $3.12, exceeding forecasts and reflecting a revenue of $1.03 billion for the quarter.
• Analysts have mixed ratings on CRL stock, with a consensus rating of "Hold" and an average price target of $175.69, indicating potential growth in the stock’s value.

Gotham Asset Management LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 25.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 154,777 shares of the medical research company's stock after buying an additional 31,087 shares during the period. Gotham Asset Management LLC owned approximately 0.32% of Charles River Laboratories International worth $23,297,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of CRL. Rothschild Investment LLC grew its position in Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares in the last quarter. Brooklyn Investment Group grew its position in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock worth $27,000 after purchasing an additional 86 shares in the last quarter. HM Payson & Co. purchased a new position in Charles River Laboratories International during the 1st quarter worth approximately $31,000. Parallel Advisors LLC grew its position in Charles River Laboratories International by 83.7% during the 1st quarter. Parallel Advisors LLC now owns 474 shares of the medical research company's stock worth $71,000 after purchasing an additional 216 shares in the last quarter. Finally, Groupe la Francaise grew its position in Charles River Laboratories International by 44.6% during the 1st quarter. Groupe la Francaise now owns 590 shares of the medical research company's stock worth $89,000 after purchasing an additional 182 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 2.4%

NYSE:CRL traded down $3.83 during trading hours on Tuesday, reaching $158.17. The company's stock had a trading volume of 1,298,573 shares, compared to its average volume of 1,234,387. The company has a market cap of $7.78 billion, a price-to-earnings ratio of -118.92, a price-to-earnings-growth ratio of 5.24 and a beta of 1.47. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02. The business's 50-day moving average is $160.83 and its 200-day moving average is $148.92. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to analysts' expectations of $983.76 million. During the same period in the prior year, the company posted $2.80 earnings per share. Charles River Laboratories International's revenue for the quarter was up .6% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Wall Street Zen cut shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 17th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a report on Wednesday, May 14th. Finally, Jefferies Financial Group upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and boosted their price target for the company from $142.00 to $195.00 in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus target price of $177.07.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).